Platelet regeneration represents an important and separate element in the engraftment process for allogeneic stem cell transplantation. Fully automated flow cytometry using blood cell counters now allows reliable quantification of reticulated platelets, expressed as the immature platelet fraction (IPF). We studied the kinetics of IPF in six patients grafted with allogeneic peripheral blood stem cell transplantation (PBSCT), 12 patients with bone marrow transplantation (BMT) and seven patients with cord blood transplantation (CBT). Preconditioning therapy caused an immediate and rapid fall in tri-lineage hematopoiesis. IPF rose transiently above 3% after a mean duration of 11 days post-PBSCT, 18 days post-BMT and 19 days post-CBT. This was 1, 4 and 13 days earlier than platelet engraftment, respectively. A linear correlation model showed a close association between the rise of IPF and tri-lineage engraftment after transplantation. IPF counting may thus provide an accessible measure of thrombopoietic activity, leading to early evaluation of marrow function and allowing monitoring of platelet regeneration.
Introduction
Allogeneic bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) have been used successfully to treat patients with high-risk or recurrent hematologic malignancies, bone marrow failure syndromes and solid tumors. 1 In addition, the recent establishment of unrelated cord blood transplantation (CBT) offers the possibility of cure even in adult patients lacking an HLA-matched related or unrelated donor. 2, 3 At present, the observation of rising peripheral blood neutrophil count offers the earliest practical measure of engraftment onset. Failure of neutrophil recovery may, however, reflect intercurrent events such as infection or graft-versus-host disease and can be difficult to interpret. Although reticulocyte counts performed by automated flow cytometric methods provide a good indicator of erythropoietic activity that may predict bone marrow regeneration, the duration, until increases in reticulocytes are seen, is usually later than or equal to that of neutrophils after transplantation. [4] [5] [6] Analysis of chimerism using fluorescence in situ hybridization (FISH) or polymerase chain reaction (PCR)-based methods can allow earlier demonstration of engraftment after transplantation, 7 but is costly and therefore unsuitable for routine monitoring.
Evaluation of thrombopoiesis by quantifying reticulated platelets, expressed as the immature platelet fraction (IPF), has recently been described. [8] [9] [10] [11] [12] Measurement of IPF is beneficial in determining whether thrombocytopenia is due to decreased production of platelets or to increased peripheral destruction, leading to avoiding the need for bone marrow examination as well as allowing optimal platelet transfusions. 9, [13] [14] [15] [16] [17] We describe herein a study of thrombopoiesis following allogeneic stem cell transplantation using an automated blood cell counter for flow cytometric techniques with a nucleic acid-specific dye in the reticulocyte/optical platelet channel. Besides, we compared the IPF to the immature reticulocyte count (IRF) 18, 19 to predict bone marrow regeneration.
Patients and methods

Patients
Between January 2005 and December 2005, 26 consecutive patients (15 men, 11 women) underwent unmanipulated allogeneic stem cell transplantation at our institute. The type of allografts used was determined at the reasonable discretion of the patients' physicians based on various factors such as the presence or absence of related donors, disease status, complications and immediacy of transplantation. A total of 25 engrafted patients were analyzed (Table 1) , excluding a 62-year-old male patient with secondary myelodysplastic syndrome receiving cord blood transplant who died of regimen-related toxicity at day 10 before engraftment. These 25 patients achieved complete donor chimerism as confirmed using FISH to detect X and Y chromosomes for recipients of sexmismatched transplants and PCR-based analysis of polymorphic microsatellite regions for recipients of sex-matched transplants. 7 All patients were administered granulocytecolony stimulating factor at a dose of 5 mg/kg/day starting 1 day after graft infusion until absolute neutrophil count (ANC) was X1 Â 10 9 /l for 3 consecutive days. Red blood cell (RBC) and platelet transfusions were given to maintain hemoglobin levels at 48 g/dl and platelet counts at 420 Â 10 9 /l. All patients provided written informed consent to participate before entry in the study.
Measurements of peripheral blood counts
Peripheral whole blood samples (3 ml) collected into ethylene diamine tetraacetic acid (EDTA)-2K anticoagulant were analyzed at our institute. A normal reference range for IPF was established using 82 samples from healthy volunteers with a median age of 31 years (range, 21-63 years) and all routine full blood count parameters including platelets within the healthy reference range. All samples were kept at room temperature until analysis and were analyzed within 2 h after collection. Samples with platelet counts o50 Â 10 9 /l were analyzed in duplicate and mean IPF was calculated and used for analysis.
IPF was measured using an XE-2100 fully automated hematology analyzer (Sysmex, Kobe, Japan) with upgraded software (XE IPF Master; Sysmex), as described previously. 8, 9 Briefly, two fluorescent dyes, polymethine and oxazine, penetrate the cell membrane, staining the DNA and RNA in white blood cells (WBCs), and the RNA in the RBCs and platelets. Stained cells pass through a semiconductor diode laser beam, and the resulting forward light scatter (cell volume) and fluorescence intensity (RNA and DNA content) are measured. A computer algorithm discriminates between mature and immature platelets according to intensity of forward-scattered light and fluorescence. The XE-2100 instrument used in the study was equipped with upgraded software for data analysis of IPF, to apply a preset gate for separating the two platelet populations. Mature platelets appear as blue dots, whereas immature platelets characterized as showing increased cell volume and higher fluorescence intensity compared to mature platelets are displayed as green dots. IPF is calculated as the ratio of immature platelets to the total number of platelets. An absolute count of immature platelet can also be obtained as absolute immature platelet count (AIPC).
The IRF was simultaneously measured in the same channel on the XE-2100 analyzer. 19 Hematologic parameters were measured as part of routine blood count analyses and results were available at the same time.
Statistical analysis
Engraftment of neutrophils, RBCs and platelets was defined as an absolute neutrophil count (ANC) 40.5 Â 10 9 /l for three consecutive measurements on different days, a platelet count 430 Â 10 9 /l for three consecutive measurements on different days in the absence of platelet transfusions for X7 days, and a reticulocyte count 430 Â 10 9 /l in the absence of RBC transfusions, respectively. Time to engraftment of neutrophils, RBCs and platelets was defined as the time from transplantation to the first day of engraftment of each lineage.
The relationship between recovery of IPF and engraftment was estimated by simple linear regression and correlation analysis. Unpaired or paired t-tests were used to determine the level of statistical difference. Values of Po0.05 were considered statistically significant.
Results
IPF values in healthy controls
IPF was measured in 82 healthy adults. Mean (7s.d.) IPF was 2.071.1% (range, 0.5-5.7%) and mean AIPC was /l). No significant differences were noted in IPF or AIPC between men and women.
Reproducibility and precision of IPF The reproducibility of the IPF counting was measured by 20 repeated analyses using six different samples. In the three samples from healthy individuals with platelet counts within the normal reference range, the average mean for the IPF was 1.9% (range, 1.7-2.0%), the average s.d. for the IPF was 0.23% (range, 0.21-0.25%) and the average coefficient of variation (CV) for the IPF was 12.6% (range, 11.0-13.9%). For the remaining three samples from individuals with low platelet counts (mean, 29 Â 10 9 /l; range, 10-50 Â 10 9 /l), these parameters corresponded to 20.9% (16.6-25.4%), 2.4% (1.6-3.6%) and 11.1% (7.9-14.2%), respectively.
Hematologic recovery after stem cell transplantation
In all patients, the ANC, reticulocyte count, platelet count, IPF and AIPC fell progressively after onset of conditioning to a nadir that persisted for a variable period, irrespective of the intensity of each preparative regimen. Figure 1 shows the mean hematologic parameters in each transplant group. PBSCT restored tri-lineage hematopoiesis the fastest, followed by BMT (Table 2) . Following the period of thrombocytopenia and o3% in IPF, a rise in IPF to X3% post transplantation occurred in all engrafted patients. The rise in IPF to X3% preceded platelet and RBC engraftment after a mean of 18 days versus 22 days (P ¼ 0.007) and 25 days (P ¼ 0.02) post-BMT, and 19 days versus 32 days (P ¼ 0.007) and 36 days (P ¼ 0.009) post-CBT (Table 2) , respectively. However, this was not evident in the PBSCT group, with mean times of 11 days, 12 days (P ¼ 0.3) and 14 days (P ¼ 0.2) to IPF rise X3%, platelet and RBC engraftment. Recovery of AIPC appeared similar to that of platelet count. No significant differences were noted between time to IPF rise X3% and time to neutrophil engraftment in each transplant group.
Relationship with the IPF rise and engraftment
The minimum of IPF ranged 0.4-2.5% following conditioning regimen, and the maximum of IPF in the early post-transplant period ranged 4.2-10.4% (Table 2 ). Based on these findings, when time to IPF rise X3.0, X3.5, or X4.0% versus time to platelet engraftment was plotted for all patients, a marked association was evident in each case (Table 3 ). The correlation was maximal when the cutoff count for IPF was set at 3.5% (Table 3 ; Figure 2a ). Of note, the IPF rise X3.0% preceded platelet engraftment in four PBSCT patients (67%), 10 BMT patients (83%) and all seven CBT patients, suggesting that detection of the IPF rise X3.0% can allow estimation of platelet engraftment after transplantation. IPF rise also predicted RBC engraftment (Figure 2c ), but appeared coincident with neutrophil engraftment (Figure 2b) .
Comparison of the IPF to the IRF
The recovery of the IRF, which was defined as an IRF value X10% according to previous reports, 14,17 took a mean of 14 days (range, 10-15 days) in patients undergoing PBSCT; a mean of 16 days (range, 13-20 days) in patients undergoing BMT; and a mean of 21 days (range, 15-29 days) in patients undergoing CBT (Table 2) , which was similar to the recovery of IPF X3% (P ¼ 0.7, 0.9 and 0.4, respectively).
Discussion
Newly released platelets contain a coarse and punctuated reticulum, and have been termed 'reticulated platelets', as the platelet analog of red cell reticulocytes. 20 The number of reticulated platelets reflects the rate of thrombopoiesis, 13, 15, 21, 22 increasing when platelet production rises and decreasing when production falls. Reticulated platelets contain amounts of cytoplasmic RNA, and can thus be distinguished from mature platelets poor in RNA by flow cytometric quantification using any fluorescent dye binding RNA. 21 Several studies have clearly shown that platelet RNA content correlates directly with megakaryocyte activity under conditions of thrombocytopenia. 13, 15, 16, 22 
Recent advances in technology enabled automatic and immediate measurement of reticulated platelets, expressed as IPF using the Sysmex XE-2100 blood cell counter with upgraded software. This instrument is reportedly useful in the diagnosis and monitoring of thrombocytopenic patients. 8, 9 A reference range for IPF in healthy individuals using this method proved to be 0.5-5.7% in the present study. This seemed comparable to the reference range of 1.1-6.1% reported by a group in London, UK 9 using the same instrument.
In evaluating thrombocytopenia during the early posttransplant period, knowing whether platelet production is developing or not is important. For this purpose, bone marrow aspiration is sometimes used to provide information on platelet production, such as the number of megakaryocytes. However, bone marrow examination is not accepted for routine clinical application, as the procedure is invasive, time-consuming and prone to subjective interpretation.
To examine whether IPF counting can solve this dilemma, we tested IPF as a predictor of the timing of platelet recovery in recipients of allogeneic stem cell transplantation. IPF transiently increased in the early post-transplant period in all engrafted patients, which may reflect an explosive increase in platelet production at the beginning of engraftment. In our study, the IPF X3.0% was the earliest predictor for platelet engraftment, and the IPF X3.5% was the most precise predictor based on the correlation analysis. The IPF rise X3% substantially preceded platelet engraftment after BMT or CBT. No such precedence was evident after PBSCT, although this finding may be attributable to rapid platelet recovery following PBSCT.
Inadequate engraftment following transplantation represents a serious problem with high mortality. Although this event occurs infrequently in patients receiving bone marrow or peripheral blood grafts, engraftment is far slower and graft failure is more likely in patients undergoing CBT.
2,3
Opportunistic infection and organ failure rise exponentially with time to engraftment, and overall long-term survival correlates closely with neutrophil and platelet engraftment after CBT. 3 Early diagnosis or prediction of engraftment failure may allow timely introduction of appropriate treatment. 23 As far as assessing marrow regeneration is concerned, IPF rise offered a particularly early and sensitive index for platelet and RBC engraftment after BMT and CBT. These findings indicate that automated IPF counting may allow a useful and early evaluation of the re-establishment of hematopoiesis in platelet and RBC lineage following allogeneic BMT and CBT. Notably, IPF rise X3% represented the first sign of hematologic recovery in all six PBSCT patients, six of 12 BMT patients (50%) and six of seven CBT patients (86%), preceding or occurring at the same time as neutrophil engraftment. However, early signs of recovery were not so apparent when considering AIPC that was gradually increased in parallel with platelet recovery. This discrepancy might be due to the fact that small changes are barely perceptible when IPF is converted to absolute numbers like AIPC.
A further advantage of IPF measurement is the ability to make clinical decisions when hematopoietic recovery appears delayed, particularly for patients at highest risk of graft failure, such as those who have received quite low doses of infused CD34-positive cells such as cord blood graft, or recipients of an allograft with some degree of HLA disparity. For such patients, close monitoring to detect any early signs of hematopoietic recovery may be easily accomplished with the IPF counter. Nevertheless, we were unable to define IPF and time points after transplantation predictive of graft failure, as only one of the 26 patients experienced graft failure in the present study. Rising IRF values, expressed as a percentage of the total reticulocyte count, is reportedly the first sign of hematologic recovery after BMT and PBSCT. 5, 6, 18, 24 The present study showed that the IPF recovered in parallel with the IRF in patients receiving allografts including a cord blood graft. When IPF and IRF were compared with respect to correlation with engraftment, contributions of IPF and IRF are almost equivalent to predict subsequent platelet and RBC engraftment in a patient undergoing BMT or CBT. On the other hand, neutrophil recovery was not predictable from either IPF or IRF, possibly resulting from the early recovery of neutrophils in this study that might be related to the reduced-intensity conditioning regimen used in the majority of the patients.
Previous reports have demonstrated that a transfusion of platelets temporarily reduces the IPF, whereas infection often raises the IPF with no subsequent increase in platelet count. 14, 17 In our study, it makes these issues complex that most allograft recipients usually not only experience clinical evidence of sepsis, but receive multiple platelet transfusions in the early post-transplant period. The present study showed no tendency that the patients receiving multiple platelet transfusions or with infection demonstrated a longer period for platelet regeneration or a longer time lag between a rise in the IPF and an increase in the platelet count.
In conclusion, a fully automated, rapid IPF counting using the Sysmex XE-2100 fitted with upgraded software provides clinically useful data on thrombopoietic activity in the immediate post-transplant period. Results are available at the same time as results for full blood counts. In addition, IPF counting can be performed on 0.1 ml of EDTA-anticoagulated blood. Such information will be an important component in determining the necessity and timing of platelet transfusions in patients with thrombocytopenia after allogeneic transplantation. Therefore, measurement of IPF should be considered as routine practice to evaluate and monitor thrombocytopenic patients following stem cell transplantation.
